Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy ELIMINATE trial is evaluating LBP-EC01 for treating urinary tract infections caused by drug-resistant E. coli Funding to support advancement into Part 2 of ELIMINATE trial RESEARCH TRIANGLE PARK,...

Locus Biosciences Announces First Patient Treated in the ELIMINATE Registrational Phase 2/3 Trial of LBP-EC01 for Urinary Tract Infections RESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered...

Locus Biosciences Announces $35 Million Financing Proceeds will support product development and expansion of in-house cGMP manufacturing capabilities Company anticipates initiating Phase 2 trial of CRISPR-Cas3-enhanced bacteriophage precision...

Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital RESEARCH TRIANGLE PARK, N.C., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Locus Biosciences, Inc. (“Locus”), a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage...

Locus Biosciences completes first-of-its-kind controlled clinical trial for CRISPR-enhanced bacteriophage therapy RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Locus Biosciences, a clinical-stage biotechnology company, announced today the completion of its Phase 1b clinical trial of LBP-EC01,...